Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

Learn more about whether Organon & Co. or Viatris Inc. is a better investment based on AAII's A+ Investor grades, which ...

Mucinex maker Reckitt Beckiser’s new “simpler and more effective organization” won’t include 190 New Jersey workers. | ...

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of ...

The revision of the outlook to negative is due to the anticipation that Organon’s leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth ...

Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is set to bolster and widen ...

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals ...

Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai ...